ALK-Abelló A/S (Nasdaq Copenhagen: ALK B; 0OIR), the Denmark-headquartered global specialty pharmaceutical company focused on allergy, has confirmed it will publish its results for the first nine months of 2026 on the afternoon of Tuesday, 17 November 2026. A live investor and analyst presentation will follow at 3:30 p.m. CET, where management will discuss both the nine-month figures and the company's outlook. The event provides investors with a scheduled opportunity to assess ALK's commercial progress across its allergy diagnosis and treatment portfolio ahead of the full financial year.

Key Points

  • ALK-Abelló A/S (Nasdaq Copenhagen: ALK B / 0OIR) is a global specialty pharmaceutical company focused on allergy, headquartered in Denmark
  • Nine-month (Q3) 2026 results will be published on the afternoon of 17 November 2026, followed by an investor presentation at 3:30 p.m. CET
  • President & CEO Peter Halling, CFO Claus Steensen Sølje, and VP Head of IR Per Plotnikof will represent the company at the event
  • Investors should watch for management commentary on the full-year outlook and progress across ALK's allergy treatment and diagnostics portfolio

ALK-Abelló Schedules 17 November Webcast for Nine-Month 2026 Financial Results

ALK-Abelló confirmed in its 10 November announcement that the nine-month 2026 results will be released during the afternoon of 17 November 2026, with a live audio webcast presentation beginning at 3:30 p.m. CET. The webcast will be available for replay on ALK's website following the event. Participants wishing to join by telephone are directed to register via a dedicated conference call link, after which dial-in details including a passcode and pin code will be provided. The presentation materials will also be published on ALK's website shortly before the meeting begins.

Peter Halling and CFO Claus Steensen Sølje to Address Investors on Outlook

Three senior members of ALK's leadership team will participate in the presentation. President and Chief Executive Officer Peter Halling and Chief Financial Officer Claus Steensen Sølje will comment on the nine-month results and the company's forward outlook, while Per Plotnikof, Vice President and Head of Investor Relations, will also be present. All three executives will be available to answer questions from investors and analysts during the session, giving market participants direct access to ALK's management at a critical point in the financial reporting calendar.

ALK's Allergy-Focused Portfolio and Global Operations Provide Context for Results

ALK describes itself as a global specialty pharmaceutical company whose activities span the entire value chain of developing, sourcing, producing, and marketing products for diagnosing and treating respiratory allergies and severe allergic reactions, including anaphylaxis, in both children and adults. Headquartered in Denmark, the company employs approximately 2,800 people worldwide and is listed on Nasdaq Copenhagen. Investors may be watching the nine-month figures for signals on commercial momentum across ALK's diversified allergy portfolio, which serves patients across multiple geographies.